All Comments by Hiroshi Mori

  1. No association detected between very-low-density lipoprotein receptor (VLDL-R) and late-onset Alzheimer's disease in Hong Kong Chinese.
  2. Evidence for presenilin-1 involvement in amyloid angiopathy in the Alzheimer's disease-affected brain.
  3. The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia.
  4. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation.
  5. Amyloid plaques in Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex contain species of A beta similar to those found in the amyloid plaques of Alzheimer's disease and pathological aging.
  6. Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease.
  7. Interaction of apolipoprotein E epsilon 4 with other genetic and non-genetic risk factors in late onset Alzheimer disease: problems facing the investigator.
  8. Levels of trkA and BDNF mRNA, but not NGF mRNA, fluctuate across the estrous cycle and increase in response to acute hormone replacement.
  9. Mechanism of action of antiinflammatory drugs.
  10. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red.
  11. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease.
  12. Congo red inhibits proteoglycan and serum amyloid P binding to amyloid beta fibrils.
  13. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect?
  14. Apolipoprotein E polymorphism in patients with Alzheimer's disease, vascular dementia and ischemic cerebrovascular disease.
  15. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability.